Foghorn Therapeutics (FHTX) Consolidated Net Income (2020 - 2025)
Historic Consolidated Net Income for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$16.5 million.
- Foghorn Therapeutics' Consolidated Net Income rose 1387.41% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.0 million, marking a year-over-year increase of 1780.47%. This contributed to the annual value of -$86.6 million for FY2024, which is 1199.48% up from last year.
- Latest data reveals that Foghorn Therapeutics reported Consolidated Net Income of -$16.5 million as of Q3 2025, which was up 1387.41% from -$18.8 million recorded in Q2 2025.
- Over the past 5 years, Foghorn Therapeutics' Consolidated Net Income peaked at -$14.3 million during Q3 2023, and registered a low of -$30.5 million during Q1 2023.
- For the 5-year period, Foghorn Therapeutics' Consolidated Net Income averaged around -$23.8 million, with its median value being -$24.1 million (2023).
- In the last 5 years, Foghorn Therapeutics' Consolidated Net Income plummeted by 6890.29% in 2021 and then surged by 4433.23% in 2023.
- Over the past 5 years, Foghorn Therapeutics' Consolidated Net Income (Quarter) stood at -$28.5 million in 2021, then decreased by 1.33% to -$28.9 million in 2022, then rose by 16.55% to -$24.1 million in 2023, then rose by 19.09% to -$19.5 million in 2024, then rose by 15.56% to -$16.5 million in 2025.
- Its last three reported values are -$16.5 million in Q3 2025, -$18.8 million for Q2 2025, and -$20.2 million during Q1 2025.